What a transplant costs: about $276,000 for the admission alone
also called cost of paediatric HSCT · bone marrow transplant cost children leukemia
A bone marrow transplant for a child with acute leukemia costs about $276,000 just for the initial hospital admission, which lasts a median of 43 days. That single admission is 80% of everything spent in the first year after transplant.
The same thing, for a scientist
In a 49-hospital Pediatric Health Information System analysis of 1,693 allogeneic HCT recipients transplanted for acute leukemia or MDS at US paediatric centres between 2010 and 2014, children under 15 incurred a median adjusted cost of $275,723 for the initial transplant admission (adolescents and young adults $338,458), with a median length of stay of 43 days and $5,838 per hospital day in children. Eighty percent of total costs from admission through one year post-HCT occurred during that initial admission. Cost drivers on multivariable analysis were increasing age, length of stay, cord blood or unrelated donor, graft-versus-host disease, infection, dialysis and mechanical ventilation.
The number, and what it is a number for3 deeper
Denominator: one allogeneic HCT episode at a US paediatric centre, 2010-2014 dollars 1.
| Measure | Children (<15 y) | Adolescents/young adults (15-39 y) |
|---|---|---|
| Median adjusted cost, initial HCT admission | $275,723 | $338,458 |
| Median cost per hospital day | $5,838 | $7,122 |
| Median length of stay | 43 days | 43 days |
| Share of 1-year total incurred in initial admission | ~80% | ~80% |
The cohort is 1,693 recipients across 49 US children's hospitals, all transplanted for acute leukemia or MDS 1. These are 2010-2014 costs; a decade of medical inflation means the current figure is materially higher, and this node does not attempt to inflate it.
Why transplant is the pivot of the economic argument
A meaningful share of infants with KMT2A-rearranged leukemia are taken to transplant, and the graph already documents the clinical ambivalence about that decision (concept-hsct-in-kmt2a-r-leukemia). The economics sharpen it.
One avoided transplant saves roughly the cost of three and a half minimum six-month infant revumenib courses at list price (~$240,000 each, see cost-menin-inhibitor-course), or about six adult months of the same drug. So a targeted agent that reliably converted a transplant candidate into a non-transplant candidate would be close to cost-neutral before counting any survival benefit, any avoided graft-versus-host disease, and any avoided late effects.
That is the strongest health-economic argument available to this project, and notably nobody has made it in print: no cost-effectiveness analysis of a menin inhibitor exists in any population (see cost-frontline-infant-leukemia-care).
The cost drivers are the complications, again
Multivariable analysis identified increasing age at HCT, length of stay, use of cord blood or an unrelated donor, occurrence of any graft-versus-host disease, infection, dialysis and mechanical ventilation as significant drivers of initial-admission cost 1.
Every one of those except donor source is a complication. This reproduces the pattern in frontline care: in paediatric leukemia, cost is a function of how badly treatment goes, not of what the treatment costs to buy. An intervention that reduces variance in outcome is worth more economically than one that reduces mean drug spend.
The family bears costs the hospital ledger never shows
A cross-sectional study of 257 caregivers of children who underwent haematopoietic cell transplantation found that 92% spent all their bank savings to cover the procedure, 67% sold assets, about 18% took leave from work, 19.5% moved to part-time work and about 18% became completely unemployed to follow the treatment 2.
That study was conducted in Iran, where transplantation is cheaper than in high-income systems and insurance coverage differs, so the dollar figures do not transfer. The pattern does, and it is corroborated in the US setting by the COG financial-toxicity data in cost-family-financial-toxicity-infant-leukemia.
| median initial admission cost usd children | 275723 |
|---|---|
| median initial admission cost usd aya | 338458 |
| cost per hospital day usd children | 5838 |
| cost per hospital day usd aya | 7122 |
| median los days | 43 |
| share of first year cost in initial admission PCT | 80 |
| cohort n | 1693 |
| centres | 49 |
| cost year range | 2010-2014 |
- An economic case built on avoided transplant collapses if the targeted agent merely defers transplant rather than replacing it. Menin-inhibitor responses in relapsed disease are frequently used as a bridge to transplant, which adds cost rather than removing it.
- Framing transplant avoidance as a saving invites payers to demand the saving be realised before the drug is paid for, which in a disease with 5 to 120 eligible patients per country per year is an outcomes-based contract nobody can administer.
- What is the cost of allogeneic HCT specifically in infants under one year, who need different conditioning, longer ICU exposure and weight-based product handling?
- If a menin inhibitor deferred or avoided transplant in infants, what fraction would have to be spared for the strategy to be cost-neutral at current list price? The arithmetic in this node suggests roughly one in three, but that has never been modelled.
- How much of the 80% of first-year cost concentrated in the initial admission is avoidable ICU time versus irreducible conditioning and engraftment?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Among 1,693 allogeneic HCT recipients for acute leukemia or MDS at 49 US children's hospitals (2010-2014), children incurred a median adjusted initial-admission cost of $275,723 versus $338,458 in adolescents and young adults, with median LOS 43 days, $5,838 versus $7,122 per hospital day, and 80% of total costs through one year post-HCT occurring during the initial admission; cost drivers were age, LOS, cord blood or unrelated donor, GVHD, infection, dialysis and mechanical ventilation.
Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study · Rangarajan HG, Smith LC, Stanek JR, et al. · Biology of Blood and Marrow Transplantation 2019What this evidence cannot show
Administrative database (PHIS), ICD-9 coded, 2010-2014 dollars, US paediatric centres only, so it excludes transplants performed at adult centres and is now a decade out of date. Costs are hospital costs, not payer-allowed amounts or societal costs. Infants are included but not reported separately, which is exactly the stratification this beat needs and does not have.
Evidence that argues against this (1)
- The $276,000 admission is roughly a fifth to a quarter of what the transplant actually costs over a life, so the entry's headline is an admission price, not a transplant price. A CIBMTR-informed lifetime cost model estimated the average per-patient medical cost of allogeneic HCT in the United States at $942,373 to $1,247,917, inflation-adjusted to 2021 US dollars, with the transplant procedure itself accounting for only 15-19% of the total and chronic graft-versus-host disease treatment for 37-53%. The range reflects assumptions about whether 15% or 39% of patients remain on chronic GVHD treatment beyond two years. Jurisdiction US, cost year 2021 USD, payer perspective US health system, source CIBMTR clinical outcomes with cost inputs from published claims analyses. Full text read at PMC11035010. Two limits that matter here: the modelled population has a mean age of 53 at transplantation and the analysis does not break out paediatric patients, so it cannot be applied to an infant without adjustment -- but it shows that the 80%-of-first-year-costs statistic in this entry is not an 80%-of-lifetime-costs statistic, and reading it as one understates the true burden roughly fourfold. Maziarz RT et al. 2023
- E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Among 257 caregivers of paediatric haematopoietic cell transplant recipients, 92% spent all bank savings on transplant costs, 67% sold assets, about 18% took work leave, 19.5% moved to part-time work and about 18% became unemployed to follow treatment.
Exploring the financial burden of pediatric bone marrow transplantation: a cross-sectional study from the caregiver's viewpoint · Soodi O, Abdollahiasl A, Amini S, Hesari E · BMC Health Services Research 2025What this evidence cannot show
Conducted in Iran with a different insurance and price structure; self-reported caregiver interviews with recall bias; heterogeneous indications (thalassaemia 18.7%, ALL 16.7%). The magnitudes do not transfer to the US or Europe; the direction does.
Evidence that argues against this (1)
- A caution on transporting the caregiver-bankruptcy numbers: the entry already notes the Iranian setting, but the childhood-cancer financial-hardship literature has since shown that the measurement instruments themselves do not transport. A group-concept-mapping study with 80 participants across 41 countries (78% low- and middle-income) built a stakeholder-derived framework of financial hardship in childhood cancer with six clusters -- medical, non-medical, assistance and support, treatment impact, family impact and caregiver impact -- and found these 'distinct in composition compared with an existing framework for adult oncology', with caregiver impact and treatment impact rated highest and impact ratings higher in LMICs than in high-income countries. So both the magnitudes and the constructs differ between settings, and the '92% spent all bank savings' figure should be read as evidence that a construct exists rather than as a transferable rate. Abstract read via PubMed; full text not read. Ritter J et al. 2024
Counter-evidence (Maziarz 2023, PMID 37364775): lifetime per-patient allogeneic HCT cost in the US is $942,373-$1,247,917 (2021 USD), of which the transplant procedure is only 15-19% and chronic GVHD treatment 37-53%. The $276,000 initial admission is an admission price; reading '80% of first-year cost' as '80% of the cost' understates the burden roughly fourfold. Adult-weighted model (mean age 53), no paediatric stratum.
economic weight of the transplant decision
one avoided transplant ~ 3.5 infant drug courses at list
caregiver burden concentrated around transplant